Intellectus Partners LLC grew its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 5.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 105,294 shares of the company’s stock after acquiring an additional 5,294 shares during the period. Intellectus Partners LLC owned about 0.41% of Ekso Bionics Holdings worth $244,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Ekso Bionics Holdings by 32.9% during the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after purchasing an additional 176,197 shares during the last quarter. National Planning Corp raised its position in shares of Ekso Bionics Holdings by 116.2% during the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after purchasing an additional 126,000 shares during the last quarter. Carl Domino Inc raised its position in shares of Ekso Bionics Holdings by 74.7% during the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after purchasing an additional 35,088 shares during the last quarter. Finally, Independence Advisors LLC acquired a new position in shares of Ekso Bionics Holdings during the 2nd quarter worth approximately $1,840,000. Institutional investors own 6.04% of the company’s stock.
In related news, insider Russ Angold sold 28,254 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $1.53, for a total value of $43,228.62. Following the completion of the sale, the insider now owns 250,678 shares in the company, valued at approximately $383,537.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders purchased 41,264 shares of company stock valued at $48,255 and sold 259,352 shares valued at $399,373. 7.10% of the stock is currently owned by corporate insiders.
Separately, Zacks Investment Research upgraded Ekso Bionics Holdings from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Friday, September 1st.
Shares of Ekso Bionics Holdings, Inc. (EKSO) traded up 1.28% on Friday, hitting $1.19. The company had a trading volume of 156,985 shares. The stock’s market cap is $30.69 million. Ekso Bionics Holdings, Inc. has a 12 month low of $0.99 and a 12 month high of $6.00. The company has a 50-day moving average of $1.21 and a 200 day moving average of $1.91.
About Ekso Bionics Holdings
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Want to see what other hedge funds are holding EKSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ekso Bionics Holdings, Inc. (NASDAQ:EKSO).
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.